Logo

ViiV Healthcare Presents Results of GSK3640254 (GSK'254) in P-IIa study for the Treatment of HIV at CROI

Share this

ViiV Healthcare Presents Results of GSK3640254 (GSK'254) in P-IIa study for the Treatment of HIV at CROI

Shots:

  • The P-IIa POC study involves assessing GSK3640254 (GSK’254- qd) in 34 treatment-naïve adults with HIV. The study is divided into 2 parts- in part 1- patients received GSK’254 (10/200mg) vs PBO for 10days and in part 2- patients got GSK’254 (40/80140 mg) vs PBO for 7days
  • The study showed the antiviral activity b/w dose and antiviral response with 140 & 200mg doses demonstrating the reduction in plasma HIV-1 RNA. The largest mean changes in viral load were -1.5 log10 & -2.0 log10 copies/ml with these doses respectively
  • These findings support its P-IIb study that evaluates GSK’254 as part of combination therapy for treatment naïve adults living with HIV

 ­ Ref: ViiV Healthcare | Image: ViiV Healthcare

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions